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1. Introduction
Calcitonin (CT) was first discovered in 1962 by Copp and
colleagues.[1] By monitoring serum calcium levels in
fasted and anesthetized dogs, it was found that, in concert
with the previously identified parathyroid hormone
(PTH), an additional hypocalcemic factor named calcito-
nin, was involved in the maintenance of blood calcium
levels. These findings were reaffirmed a year later by
Kumar et al.[2] Despite initial experimentalists ascribing
a parathyroidal origin for CT, it was soon determined to
be a thyroid hormone.[3] The 32 amino-acid sequence of
human calcitonin (hCT) was first determined in 1968, and
in the following years, several other CT variants were dis-
covered and sequenced, including the oft-studied bovine,
porcine, and salmon CTs.[4–7] All sequenced CTs are 32
residues in length and have an intramolecular disulfide
bridge (Cys1-Cys7), but sequence homology varies signifi-
cantly from species to species, with hCT differing from
other CTs by as few as 2 residues (murine CT) or as
many as 19 residues (ovine CT).[8,9] Interestingly, the pres-
ence of the N-terminal disulfide bond is well conserved
across all known calcitonin sequences, a feature common-
ly thought to reduce amyloidogenic aggregation.[10] A
Abstract : Under appropriate conditions, peptides and pro-
teins can assemble from their native state into prefibrillar
oligomers and then mature into fibrillar aggregates. This
transition forms the molecular basis of several pathologies,
often related to the deposition of these amyloid fibrils. Sev-
eral hormone peptides involved in fundamental biological
processes have the tendency to self-assemble into amyloid
fibrils, resulting in a loss of their native functions, and more
importantly, entailing devastating consequences, such as
the formation of amyloid depositions. Calcitonin is a 32
amino-acid hormone peptide that can be considered a mo-
lecular paradigm for the central events associated with hor-
mone misfolding. Calcitonin in its native form is involved in
various physiological functions, including mediating calcium
homeostasis and maintaining bone structure. It is the latter
function that has motivated the use of calcitonin as an
aqueous therapeutic agent for the treatment of bone-related
pathologies such as osteoporosis and Paget’s disease. De-
spite some success as a therapeutic, calcitonin’s ability to
control these diseases is limited by its aggregation along
the canonical amyloid aggregation pathway, compromising
its long-term stability as a therapeutic agent. A better under-
standing of the misfolding process would not only provide
the structural basis to improve calcitonin’s long-term stabili-
ty and activity as a therapeutic, but also provide valuable in-
sights into pathological aggregation of other amyloids. In
this work, we review the physiological roles of calcitonin, its
structure, and aggregation process, and consider the effects
of calcitonin’s structure on its role as a therapeutic.
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comparative alignment of several commonly studied calci-
tonin peptide sequences is shown in Figure 1.
Despite the sequence diversity among CT variants, all
CTs have been shown to aggregate into amyloid fibrils
when concentrated in aqueous conditions.[11–14] The term
“amyloid” references a specific type of supramolecular
protein/peptide fibrillar architecture in which monomeric
subunits are stacked along the fibril axis through intermo-
lecular hydrogen bonds and electrostatic interactions be-
tween b-strands.[15,16] Such an amyloid fold was structural-
ly characterized for aggregated calcitonin peptides by the
presence of b-rich conformation in hCT and the typical
cross-b structure in salmon CT by X-ray diffraction.[11,17]
This type of aggregation behavior and secondary struc-
ture change is observed in numerous peptides, and similar
conformational diseases have been attributed to a wide
variety of pathologies.[18] A significant number of human
amyloid peptides have been found to play a role in con-
ferring pathological conditions to propagate diseases, in-
cluding the extensively studied amyloid-b, human islet
amyloid polypeptide (hIAPP), and a-synuclein peptides,
which are implicated in AlzheimerQs disease, type 2 diabe-
tes mellitus, and ParkinsonQs disease, respectively.[19–21]
Importantly, amyloids can reveal infectious properties, as
has been demonstrated for the prion protein.[22] Aggrega-
tion products and/or intermediates of these peptides/pro-
teins have been shown to be toxic to various cell types or
to drastically perturb the cellular functions.[19–21]
The aggregation process of these peptides is thought to
be highly conserved, despite differences in primary se-
quences.[23,24] For a detailed background and more details
on the topic of amyloid aggregation, readers are referred
to recent review articles in the literature.[16,25–29] Briefly,
unstructured monomers fold and combine to form small,
intermediate aggregates (oligomers) during a period
called the lag phase. Oligomers then gradually progress
to generate larger protofibrillar species. Upon the forma-
tion of a critical nucleating species, amyloids can self-tem-
plate and undergo rapid fiber growth occurring during
the elongation phase. Eventually, an equilibrium is
reached where maximal fiber content is achieved, known
as the plateau phase. This description of amyloid aggrega-
tion is oversimplified; however, in reality, a complex
amalgamation of off-pathway aggregates, species metasta-
bility, and heterogeneity serve to obfuscate the determi-
nation of the driving factors and intermediate species in
the fibrillation and toxicity of amyloidogenic sequences
(Figure 2). Additionally, aggregation is sensitive to
a range of environmental factors, including buffer compo-
sition, salt, pH, lipids, and metals, highlighting the diffi-
culties inherent in generating an all-inclusive model of
amyloid aggregation.[16,20] Although amyloids were origi-
nally a species of interest in disease due to their propensi-
ty to form readily identified plaques, recent evidence has
shifted focus away from mature aggregates and towards
early oligomers as the putative pathological species in
amyloid-related diseases.[16,20,21] Significant efforts are on-
going to elucidate the mechanism(s) of toxicity and iden-
tify the toxic species in amyloid-related diseases.
Figure 1. Amino-acid sequence alignment of the commonly stud-
ied human, bovine, porcine, salmon, and eel calcitonin. All sequen-
ces contain a disulfide bridge between residues 1 and 7, with 8
residues being conserved in all species (*), primarily at the N-termi-
nus. C-terminal amino-acid sequences vary significantly between
different homologues. Evidence for the evolutionary divergence of
different CT sequences can be seen in the relative conservation of
CT between more recently diverged species. Eel and salmon CT
(eCT and sCT) differ at only 3 locations (orange boxes), with bovine
and porcine CT (bCT and pCT) also differing at 3 (blue boxes),
whereas mammalian and fish CTs maintain less than 50% sequence
homology. Colors describe residues of similar chemistry, asterisks
denote fully conserved residues, and periods and colons indicate
weak and strong conservation of amino-acid chemistry, respective-
ly.
Figure 2. Pathway of typical amyloid aggregation pathway. The il-
lustration presents a simplified overview of the process. Initially un-
structured monomers aggregate into low molecular weight oligo-
mers, which further aggregate into larger soluble oligomers during
the lag phase. Upon formation of a critical nucleus/protofibrillar
species, with a first time-determining rate constant, k1, aggregation
is self-templated and fibril elongation progresses rapidly through
the addition of monomers or small oligomers in the elongation
phase, with a second time-determining rate constant, k2. Eventual-
ly, fiber formation rates equilibrate, with breakage rates and fiber
content remaining constant; this is known as the plateau phase.
Typically, a majority of initial monomers are sequestered in fibrils,
but small aggregates persist even after fibrillation is complete. This
picture is complicated by the number of off-pathway intermedi-
ates, which provide alternative pathways to fibrils (A, C) and amor-
phous nonfibrillating aggregates (B). Secondary structural shifts in
the monomer to b-sheet morphology (A) and the formation of a-
helical peptide micelles (C) as critical species have also been pro-
posed as steps in the amyloid cascade.
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The amyloidogenic aggregation of CT presents multiple
practical challenges, both in normal bodily function and
in therapeutic applications. While multiple variants of CT
are known to be toxic and form membrane-permeabiliz-
ing oligomers in vitro, the roles that such behaviors play
in vivo, if any, are not as well established as in other amy-
loids.[12,30–33] To date, such behaviors have not been shown
to have any significant roles in disease pathologies,
though membrane interactions do hold relevance for both
biological function and drug delivery. Studies of CT have
revealed that it has skeletoprotective properties mediated
through interactions with the calcitonin receptor (CTR),
leading to its use as an osteoporosis therapeutic agent.[8,34]
Aggregation, however, remodels the monomeric subunits
of CT and decreases their free concentration, consequent-
ly preventing the activation of CTRs.[35,36] Efforts to
combat this limited bioavailability have led to the re-
placement of hCT, as a therapeutic agent, with the
slower-aggregating salmon CT (sCT). However, not only
does sCT therapy cause immune response correlated
complications, but hCT has also been found to be more
potent than sCT under conditions where aggregation was
controlled.[36–38] Such considerations highlight why there is
significant interest in manipulating the aggregation and
structural remodeling of both human and salmon CT for
therapeutic purposes. This review will examine the role of
CT in normal bodily function, its use as a therapeutic
agent, and focus on how recent results and advances in
structural understandings of the aggregation pathway
relate to CT biology and therapy.
2. Production and Expression
The first evidence of the existence of a hypocalcemic hor-
mone was provided in 1962 by Copp et al.[1] Using perfu-
sion studies, it was found that decreases in serum calcium
levels occurred too rapidly to be caused solely by changes
in the expression of the previously known hypercalcemic
PTH. This behavior was independently reproduced within
the next year, and parathyroidectomy experiments initial-
ly suggested a parathyroidal origin for CT.[2] Further ex-
periments revealed the true source of CT (then called
thyrocalcitonin to distinguish it from the thought-to-be
separate calcitonin) to be the thyroid.[3] Immunofluores-
cence experiments later determined CT to be produced
solely and specifically in thyroid C-cells.[39]
The synthesis of CT is explained in detail in other re-
views.[8,40] Briefly, CT is coded for by the CALC I gene.
Splicing of the gene transcript at exon 4 yields CT in thy-
roid C-cells, with alternative splicing producing calcitonin
gene-related peptide (CGRP), a potent vasodilator, in
neural cells. Both CT and CGRP are part of the calcito-
nin family, along with the structurally similar peptides
hIAPP and adrenomedullin (AM), although unlike
CGRP, hIAPP and AM are not alternative splice prod-
ucts for CT.[41] The 32-residue mature CT, with a disulfide
linker between residues 1 and 7, is subsequently released
from thyroid C-cells following cleavage from a larger pre-
cursor protein.[8,40]
3. Physiological Roles
In the decades following CTQs discovery, research has re-
vealed it to have additional physiological roles. Most
prominent among these is its role in skeletal protection,
with hypercalcemia prevention and gastrointestinal inter-
actions being secondary roles. However, some studies
have shown minimal metabolic deviations upon removal
of CT, leading to speculations regarding the significance
of CTQs physiological role.[42] Here we discuss the roles of
CT in skeletal protection and hypercalcemia prevention
in the body, and consider the evidence for a role in gas-
trointestinal function.
3.1 Skeletal Protection
CTQs most prominent physiological role is its interaction
with the skeleton to moderate calcium homeostasis be-
tween blood and bone. CT serves to maintain bone mass
primarily by inhibiting osteoclasts, a bone-associated cell
type responsible for bone resorption.[43–45] CTQs interac-
tions with osteoclasts are mediated by the CTR, a G pro-
tein-coupled receptor widely expressed on osteoclast
membranes.[46] Upon activation by CT, CTR causes
a prompt loss in osteoclast ruffled border, a decreased
ability of osteoclasts to acidify the bone-cell interstitial
space, and decreased cellular motility.[47–49] All of these ef-
fects inhibit osteoclast activity and lead to decreased
bone resorption and increased skeletal mass. The related
amyloidogenic peptides CGRP and hIAPP have demon-
strated an ability to activate CTR-mediated inhibitory
pathways in osteoclasts, although their interaction and
subsequent inhibition is far weaker than the native sub-
strate CT.[8] The relative affinity of the CTR for different
members of the calcitonin family is mediated by receptor
activity modifying proteins (RAMPs), and as such, eluci-
dating the behavior of RAMPs is the subject of signifi-
cant scientific effort.[20,50,51]
In addition to interactions with the CTR, CT has other
direct effects on osteoclast function. CT can alter the
phosphorylation state of the focal adhesion proteins pax-
illin, FAK, and Pyk2.[52] A CT-dependent disruption of
the actin-ring structure associated with the sealing zone
of osteoclasts has also been observed.[52,53] Loss of focal
adhesions leads to decreased efficiency in resorption and
eventual decline in overall osteoclast numbers.[8] CT can
also form calcium permeable pores in lipid bilayers, with
some claiming that such ion flow could lead to osteoclast
detachment from the bone matrix.[32,33,54,55] A role for cal-
cium permeable CT pores in vivo requires further explo-
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ration, although calcium-dependent alterations of osteo-
clast function are known.[56,57]
Interactions between CT and two other bone-related
cell types, osteoblasts and osteocytes, have also been ob-
served, although such interactions are poorly understood.
CT administration has the conflicting actions of both de-
creasing osteoblast function and enhancing osteoinduc-
tion.[58,59] Such behaviors lead to decreased and increased
skeletal strength, respectively, confounding efforts to de-
termine the function of CTQs interaction with osteoblasts.
CT also protects both osteoblasts (no CTR expression)
and osteocytes (CTR expression) from apoptosis, indicat-
ing an apparently CTR independent interaction with such
cells.[60] In addition, osteocyte production of sclerostin,
a protein associated with a decrease in bone growth, is in-
duced by sCT.[61] These behaviors have led some to sug-
gest that CT regulates bone turnover through both osteo-
clast and osteocyte interactions.[62] Overall however, the
role of CT in mediating osteoblast and osteocyte function
remains unclear.
Several experiments where thyroidectomy had no sig-
nificant effects on long-term bone mass have challenged
the significance of CTQs role amongst the range of bone-
regulating hormones.[42,63] Experiments have also surpris-
ingly shown increased bone mass in CT/CGRPKO mouse
models, although such results are confounded by the
action of CGRP.[64] Additionally, complications from cort-
ical porosity and overactive bone resorption were ob-
served at 12 months of age in the CT/CGRPKO mouse
models.[65,66] The release of osteoclasts from the inhibitory
effects of CT after prolonged exposure and the degrada-
tion of hCT in human serum are also well-established
phenomena, suggesting the effect of hCT on bone cells is
short-lived.[67,68] It is thus likely that CTQs primary contri-
bution to bone physiology is in short-term bone remodel-
ing, or under conditions of significant calcium stress.[62,69]
In particular, CT is believed to play a significant role in
calcium homeostasis during pregnancy and lactation,
when maternal bone mass is under pressure from the cal-
cium demands of the fetus or infant. CT stimulates the
production of 1,25-dihydroxyvitamin D3 (1,25D, the
active form of vitamin D), with elevated CT and 1,25D
levels being associated with pregnancy and lactation, an
apparently contradictory relationship, given the role of
1,25D in promoting resorption.[70–74] However, CT has
also shown the ability to increase intestinal absorption of
calcium, and thus, it appears as if CT could serve the dual
roles of increasing dietary calcium uptake, and promoting
calcium transfer from bone to serum (through 1,25D)
during lactation and pregnancy.[73] This behavior would
both protect the maternal skeleton and ensure sufficient
calcium delivery to the fetus or infant. In a CT Null
mouse model, the bone-mineral loss during lactation and
the time for bone mass to return to normal were both in-
creased by the lack of CT.[72] Treatment with sCT rescued
mineral loss and time to return to baseline.[72] As such,
a heightened physiological role for CT during pregnancy
and lactation when the mother is under elevated demand
for calcium, has been proposed.[70,72,75]
3.2 Hypercalcemia Prevention
The potential for CT to counteract hypercalcemia has
been implied since its discovery.[1,2] While it exhibits no
ability to directly sequester or transfer calcium, CTQs hy-
pocalcemic function can be explained by its inhibition of
osteoclasts; a decrease in bone resorption and transfer of
calcium from bone to blood would decrease serum calci-
um levels. CT in healthy individuals under normal calci-
um load has a minimal effect, but shows an ability to de-
crease serum calcium under conditions of endogenous ad-
dition of calcium or high bone turnover.[69,72,76–78] As such,
it has been theorized that under normal conditions (no
exogenous load, normal bone turnover), PTH governs the
efflux of calcium from bone, with the influx being gov-
erned by the normal concentration gradient of calcium.
Meanwhile, under conditions of acute hypercalcemia, CT
can decrease the efflux of calcium from the skeleton, and
thus, reduce serum calcium levels through its inhibition of
osteoclastic activity.[79,80] Such a view is in keeping with
the observed behavior of osteoclastic release from CT in-
hibition. It is also supported by the upregulation of CT
under conditions of high serum calcium, and the suscepti-
bility (and subsequent CT-based rescue) of CT KO mice
to hypercalcemia.[62,81]
3.3 Gastrointestinal Function
Some evidence suggests that CT could also play a role in
gastrointestinal function. Intestinal absorption of calcium
is increased by CT.[73] Elcatonin, a synthetic eel calcitonin,
has been shown to inhibit gastric and duodenal ulcers.[82]
Calcitonin receptor-like receptors have been localized to
the human GI tract, and the peptide hormone gastrin, re-
sponsible for the secretion of gastric acid by parietal cells,
significantly upregulates CT secretion.[75,83,84] A similar
effect has been found for several other gastrointestinal
hormones, as well.[85] The studies on GI hormone-induced
CT secretion were, however, conducted with surgically
isolated thyroid glands in situ with direct exposure of the
thyroid to GI hormones; thus, it is unclear if the response
has any biological significance. Overall, the interplay of
CT and gastrointestinal function, if any, is still to be deter-
mined.
4. Structural Studies on Calcitonin Aggregation
CTQs aggregation in solution is associated with noncova-
lent supramolecular assembly, leading to the precipitation
of the peptide. At the macroscopic level, it results in
sample gelation. Initial structural investigation of CT ag-
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gregation was primarily focused on these end-stage aggre-
gates.[11,86–89] Work by Arvinte and colleagues provided
one of the first studies focused on the structure and kinet-
ics of hCT fibrillation.[11] Arvinte found higher peptide
concentrations correlate with decreased lag time, a behav-
ior that has been reproducibly observed for sCT, hCT,
and other amyloids, both experimentally and in simula-
tions.[88,90–92] hCT also showed a propensity to form well-
ordered fibrillar aggregates, another common characteris-
tic of other amyloidogenic sequences (Figure 3).[20,88,93–97]
TEM image of hCT indicates that short fibrils were ob-
served at pH 7.5, while long twisted fibrils were observed
at pH 3.3 (Figures 3B and 3C).[98] Interestingly, hCT ex-
hibited both a-helical and b-sheet structures in end-stage
fibers, a deviation from the canonical view of amyloid
peptides as maintaining a stable, exclusively b-sheet con-
formation content. Further studies have demonstrated
that while a-helical motifs may exist in the final equilibri-
um mixture, fibril morphology primarily relies on b-sheet
conformation.[12,32,98–103] Figure 4 shows typical NMR fin-
gerprints, based on solution and solid-state NMR, of hCT
in various forms (soluble and aggregated in mature fi-
brils).
Subsequent studies have yielded more detailed struc-
tural data on the amyloid fibrils of CT. Based on solid-
state NMR spectroscopy, Naito and colleagues have re-
vealed distinct behaviors for the central, N-terminal, and
C-terminal regions of hCT. Early aggregates contain
a central a-helix, with a loop structure at the N-terminus
and a random coil C-terminus (Figure 5, monomer).[98]
During fibril formation, the central helix converts to a b-
strand, with the N-terminal loop remaining unchanged.[98]
The formation of this central b-strand also results in
a shorter C-terminal in random coil conformation, with
residues closer to the central region incorporating into
the b-strand (Figure 5, fiber).[99] The observation of a cen-
tral a-helix to b-strand conversion with a structured N-
terminus and unstructured C-terminus has been con-
firmed in follow up studies by both Naito and
others.[86,87,93,103–106] These secondary structural changes in
CT fibrillation persist in both neutral and acidic environ-
ments, but pH-dependent differences in the relative
Figure 3. Transmission electron microscope images reveal polymorphic low-resolution structures of human calcitonin aggregates formed
from solution samples prepared under different conditions. A) Short straight fibrils formed 90 min after dissolving 22.5 mgml@1 of hCT in
20 mM sodium phosphate buffer (100 mM NaCl, pH 7.5) at 20 8C. B) Long twisted ribbon type fibrils formed 45 days after dissolving
22.5 mgml@1 of hCT in aqueous acetic acid (15 mM, pH 3.3) at 20 8C. C) Spherical aggregates together with short fibrils formed 4 days after
dissolving 40 mgml@1 of hCT in HEPES solution (20 mM, pH 5.6) at 20 8C. D) Dense fibrils of hCT formed from 120 mM initial monomer con-
centration at 25 8C in 20 mM sodium phosphate buffer (100,000V magnification; unpublished results from the Ramamoorthy group). TEM
images of 0.3 mM samples of hCT after 36 hours of incubation at pH 7.4 and 298 K: E) without; and F) with 3 molar equivalents of EGCG
(epigallocatechin 3-gallate, a polyphenolic compound extracted from green tea). Absence of amyloid fibers in (F) suggests that EGCG effec-
tively inhibits the aggregation of hCT, which has been further confirmed by NMR experiments; mechanistic details have been reported else-
where by the Ramamoorthy group (Ref. [100]). TEM images A)–C) were adapted from Ref. [106] , while E) and F) were adapted from Ref.
[100].
Isr. J. Chem. 2017, 57, 634 – 650 T 2017 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.ijc.wiley-vch.de 639
Review
length and orientation of b-sheet motifs in the fibril do
arise.[93,99,106] It has been suggested that the charge states
of the amino acids Asp15, Lys18, and His20 mediate this
effect.[105] It is likely, therefore, that electrostatic interac-
tions play an important role in the structure and packing
of CT fibers, as has also been observed for other amyloid
peptide assemblies.[107,108]
The conformation of fibrils in acidic and neutral condi-
tions was investigated by solid-state 13C NMR spectrosco-
py using site-specific 13C labeled hCT.[98] The results indi-
cate that the fibrils form an antiparallel b-sheet structure
around Gly1- to Phe22 at pH 7.5 (Figure 5).[98] On the
other hand, the fibrils of hCT at pH 3.3 were interpreted
as forming a mixture of antiparallel and parallel b-sheets
(Figure 5).[98] Detailed b-strand packing in the hCT fibril
grown at pH 7.5 has been described by an accurately
measured interatomic distance in the D15FNKF19 frag-
ment, which is known as the minimum size of the peptide
fragment to form a fibril.[99] 13C and 15N nuclei in [1-
13C]Phe16 and [15N]Phe19 of the D15FNKF19 fibril are lo-
Figure 4. Solution and solid-state NMR spectra of hCT in various forms. A) Solution NMR spectra of hCT peptide, in the soluble form (in
blue) and in its aggregated form (in red). Signal loss in the spectra of the aggregated form is due to the very slow molecular tumbling that
exhibits prefibrillar and fibrillar nanoobjects. B) Solid-state NMR spectra of the hCT fibrils. Cross-polarization experiment (in black) probes
the residues in a rigid conformation. The 13C CPMAS spectrum shows relatively high resolution, indicative of a well-ordered core. INEPT-
based polarization transfer from 1H to 13C (in blue) is used to probe mobile residues (faster than the microsecond timescale of motion). The
absence of signals in the INEPT experiment indicates that all residues within the hCT peptide sequence adapt a rigid conformation. C) Two-
dimensional 1H/1H NOESY spectrum (the Ha-HN region) of 1mM hCT (in 2 mM sodium phosphate buffer, 7% D2O, 50 mM NaCl, pH=2.9)
obtained at 900 MHz proton resonance frequency with a 300 ms mixing time (spectrum adapted from Ref. [100]). NOEs were used to deter-
mine the structure of the peptide as reported elsewhere (Ref. [100]). D) Proton NMR spectra of hCT at pH 7.4 recorded at 600 MHz shows
the temperature-dependent spectral resolution; line broadening of amide-NH resonances and line narrowing of aliphatic resonances were
observed as the sample temperature was increased from 10 to 40 8C, demonstrating the feasibility of probing the aggregation at atomic-
level resolution by NMR spectroscopy (unpublished results from the Ramamoorthy lab).
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cated one residue away from the known actual hydrogen-
bonding location in a head-to-tail antiparallel b-sheet
structure.[99] The phenyl rings of Phe16 and Phe19 resi-
dues are facing each other on the same side of the b-
sheet, to be able to contact, via p-p interactions, as illus-
trated in Figure 5. By assuming that the D15FNKF19 forms
the core part of the hCT fibrils, the packing scheme of
the hCT fibril at pH 7.5 is drawn as in Figure 5.[99]
Several other experiments have been carried out to
probe the effect of electrostatic interactions on the aggre-
gation kinetics of CT. At neutral pH, hCT contains a neg-
ative charge at Asp15, and positive charges at Lys18 and
the C-terminal amide.[105] At acidic pH, His20 and Asp15
both become protonated, changing hCTQs charge from
+1 to +3.[105] Increasing the peptide charge by decreasing
the pH has been shown to slow aggregation in CT, yet
substitution of the Asp15 with an Asn (increasing the net
charge from +1 to +2 at neutral pH) led to accelerated
fibrillation kinetics.[100,105] In contrast, a comparison, at
neutral pH, between hCT (+1 charge) and the slower-ag-
gregating sCT (+3 charge) contradicts the behavior of
the Asn-hCT mutant relative to the wild-type.[109] The
role of electrostatic interactions in CT-aggregation kinet-
ics must therefore be more complicated than simple net-
charge considerations. It is worth noting that all of hCTQs
charged residues occur in the central region (Figure 1),
associated with rapid formation of a-helices. Consequent-
ly, hydrophobic interactions that drive fibril formation
likely confound efforts to elucidate the precise role of the
charged residues in kinetics.
NaitoQs work has also implicated oligomeric intermedi-
ates with a spherical shape as important in seeding fi-
brils.[93] Such intermediates were found to serve as nuclea-
tion sites for the growth and elongation of mature CT
fibers, and appeared to be critical for fibril formation.
While the structure of these fibers is similar to those pre-
viously observed, the biological relevance of the spherical
intermediates is uncertain due to the known aggregation-
inhibiting properties of the fibrillation environment.[93]
NaitoQs studies have also demonstrated the importance of
aromatic residue p-p stacking interactions for maintaining
fibril stability.[106] This p-p stacking is viewed as an impor-
tant driving force during the self-assembly of amyloid fi-
brils, considering its energetic contribution to the inter-
subunit molecular interaction network and its impact into
the directionality of the subunit stacking.[110] In this
regard, Metrangolo and coworkers have recently shown
that iodination of the two phenalanine residues of hCT
can amplify the fibril formation, leading to a 30-fold
more efficient aggregation process.[111] The aromatic
stacking is thought to be a major contributor to the kinet-
ics difference between sCT and hCT, given that the in-
volved central aromatics Tyr12, Phe16, and Phe19 in hCT
all change to Leu in sCT (Figure 1). Such alterations
would eliminate any stabilizing p-p interactions, thus de-
creasing the stability of critical aggregation species and
slowing fibrillation.
Similar to other central amyloidogenic peptide frag-
ments, the central hCT pentapeptide fragment
D15FNKF19 has been shown to be required for fibril for-
mation.[103] The central residues of CT are believed to
form the fibrillar core of the amyloid fibrils, and the pen-
Figure 5. NMR structures of monomer, oligomer, and fibril stages
of hCT. The monomer and fibril structural models are based on
NMR experiments at pH 3.3, and the oligomer structural model is
based on NMR experiments at pH 3.3 and 7.5. The monomer exhib-
its an N-terminal loop, central a-helix, and C-terminal random coil.
During early stages of oligomerization, the helix transitions to a b-
hairpin, with the N- and C-termini remaining unchanged. This b-
structure incorporates more C-terminal residues, with further ag-
gregation, and eventually gives rise to a distinctive b-sheet mor-
phology of amyloid fibrils. At low pH, the charge states on residues
15, 18, and 20 allow for both parallel and antiparallel b-sheet stack-
ing. At neutral pH, residue 15 and 18 possess negative and positive
charges, respectively; thus, fibrils show antiparallel b-stacking. The
structures show one possible pathway from a monomeric to
a fibril structure, although other intermediates along the way are
likely.
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tapeptide aggregates into fibers with a morphology simi-
lar to that formed by the full-length peptide.[98,101] This
fiber formation is noteworthy, due to the fairly hydrophil-
ic nature of the pentapeptide, a challenge to the theory
that amyloid aggregation is primarily driven by hydropho-
bic interactions,[112] and rather, it suggests a combined
mechanism of hydrophobic and hydrophilic interactions,
as have been observed, for example, in polyQ disease-re-
lated peptides.[113] Like the full-length peptide, it is possi-
ble that aromatic interactions play a major role in stabi-
lizing the fibers, although experiments performed with
other short peptide fragments from different amyloid
peptides counter this claim.[103,114] Such experiments in-
stead suggest that aromatic interactions are not necessary
for fibrillation, but simply alter fibril structure. Regard-
less, experiments have clearly demonstrated the
D15FNKF19 hCT fragment to be a key sequence in media-
ting fibril formation. A second amyloidogenic sequence
of hCT towards the N-terminus, T6CMLGT11, has also
been predicted, with an analog having been demonstrated
to form amyloid fibrils, though the relevance of this frag-
ment remains up for debate.[115]
A commonly observed feature of both sCT and hCT ag-
gregation is the formation of a-helical intermedi-
ates.[11,13,14,103,116–119] Both the full-length CT and the
D15FNKF19 pentapeptide have exhibited such structures,
with a-helical intermediates forming rapidly and being
highly stable.[98,99,103] The specifics of the progression from
a-helical intermediates toward the mature fibrillar struc-
ture are influenced by a number of factors, including pH
conditions, the presence of lipids, buffer composition, and
the concentrations and types of salts and metal
ions.[13,33,93,96,98,99] Despite this variability in fibrillation, a-
helical intermediates have been observed under a range
of conditions, and play a significant role in the biological
function of CT.[11,14,103,114,120–122] Regarding the a-helical in-
termediate, it is reported that dimerization of hCT stabi-
lize the a-helix under aqueous TFE solutions, leading to
the long fibril formation.[123] Within individual CT mono-
mers, there are often multiple secondary structural motifs
present that depend on the aggregation environment and
could influence peptide behavior, but given the ubiquity
of a-helical intermediates, it seems generally accepted
that they are a key species in the in vivo aggregation of
CT.[98,99,104]
4.1 Kinetic Analysis of Fibril Formation and Inhibition of
Calcitonin
Kinetic analyses of hCT were performed by using solid-
state 13C NMR to gain insight into the mechanism of
fibril formation and inhibition.[93,98,99,105,106] The increased
13C CP/MAS NMR intensities suggest that the fibrillation
can be explained by a two-step autocatalytic reaction
mechanism, in which the first step is a homogeneous asso-
ciation to form a nucleus or intermediate, and the second
step is a catalytic heterogeneous fibrillation to elongate
the fibril. The rate constants for the first step (k1) and the
second step (k2) were analyzed using the following equa-
tion:[98]
f ¼ 1fexp½ð1þ 1ÞktA @ 1gf1þ 1 exp½ð1þ 1ÞktAg ð1Þ
where f represents the fraction of fibrils among the total
population of peptides among the total population of
peptide molecules: 1=k1/k ; and k=ak2, where the initial
peptide concentration is given by a. The two-step autoca-
talytic reaction mechanism applied to kinetic analysis of
hCT using Eq. (1) was found to be mathematically identi-
cal to the Finke-Watzky (W-T) two-step mechanism,
which is also used for analysis of the kinetics of fibril for-
mation.[124] This kinetic analysis provide us with rate con-
stant of the first step (fibril nucleation), k1, which is re-
sponsible for the lag time of the fibrillation, and the rate
constant of the second step (fibril elongation), which is
responsible for the rate of fibril elongation.
In the kinetic analysis at pH 3.3, the rate constant for
the first step, k1, values are three orders of magnitude
smaller than that of the second step, k2, values for the
13C
labelled hCT samples (Table 1).[98] These results suggest
that the first homogeneous nucleation process is much
slower than the second heterogeneous fibrillation process.
A fibrillation process derived by the kinetic analysis, as
well as the conformational transition, is illustrated in
Figure 2. Using this result, an a-helical bundle (micelle)
has to change its conformation from a-helix to a b-sheet
simultaneously in the first nucleation process, while one
a-helix can be converted to a b-sheet in the second heter-
ogeneous fibrillation process. These findings, based on 13C
NMR experiments, imply that it is sufficient to consider
a two-step reaction for the fibrillation kinetics. The time
course of the fibril formation at pH 7.5 was also examined
by CD measurement, because it is not possible to deter-
mine the fast fibrillation rate at pH 7.5 by 13C NMR
measurements.[98] The monomeric component assigned to
the random coil (205 nm) in the CD spectra decreased
gradually as a result of fibril formation in much lower
concentrations than those for NMR measurements. Con-
sequently, the kinetic parameters are observed in the
same way, and it is found that the fibril formation after
the nucleation at pH 7.5 occurred much faster than that
at pH 3.3, because the value at 7.5 was three orders of
magnitude larger than that at pH 3.3, because k1 values
were not different among them. It is revealed that k1
values are not correlated with pH and concentration from
the experimental observations.[98,105]
The mutation from the aromatic side-chain (Y12, F16,
F19) in hCT to Leu residues (TL-, F16L-, and F19L-hCT)
resulted in a significantly slower elongation rate of fibril
formation, k2, specifically at neutral pH conditions than
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that of hCT. In the case of hCT, since the aromatic side-
chains are Tyr12, Phe16, Phe19, and Phe22, the side-chain
of Phe16 and Phe19 could engage in p-p stacking in an
antiparallel b-sheet. If the Phe residue plays an essential
role in determining the molecular packing, the side-
chains of Asp15 and Lys18 changing at neutral pH might
help the intermolecular packing, because the residues are
located very closely to Phe16 and Phe19. In the hCT
mutant, lack of Phe16 and Phe19 interaction causes sig-
nificant instability, as compared with the Wt-hCT fibril.
This instability of the b-sheet causes the reduction of k2
values (Table 1).[106]
The two-step autocatalytic reaction mechanism was ap-
plied to the analysis of the kinetics of hCT fibrillation in
HEPES solution.[93] The nucleation rate, k1, in HEPES so-
lution at pH 5.6 was 2.98X10@10 s@1, which was significant-
ly lower than the rate in neutral solution (k1=2.79X
10@6 s@1). The fibril-elongation rate, k2, in HEPES solu-
tion at pH 5.6 was 1.98X10@3 s@1M@1 (Table 1). This result
indicates that HEPES shows a much slower fibril-nuclea-
tion rate than the fibril-elongation rate. Asp15 (negatively
charged) and Lys18 (positively charged) in hCT may have
strong electrostatic interaction with amino (positively
charged) and sulfonyl (negatively charged) groups in
HEPES, respectively. Because of the amphiphilic nature
of the N-terminus, a-helices associate with each other to
form micelle-like spherical aggregates. These aggregates
may be further stabilized by the interaction with HEPES
at the surface in the interfacial region of spherical aggre-
gates, leading to the slow rate of nucleation. Because the
spherical intermediates are stabilized, it is possible to ob-
serve the spherical intermediate of hCT in HEPES solu-
tion by TEM (Figure 3C).[93]
4.2 Membrane Interactions
CT-membrane interactions have been studied extensively,
both for the possibility of physiological relevance via
pore formation, and for the increasing prevalence of
lipid-based delivery options for therapies.[32,33,104,125–127] As
with other amyloid peptides, CT preferentially interacts
with membranes containing anionic lipids, cholesterol,
and GM1 ganglioside.[16,20,24,32,114,128,129] a-helical motifs in
CT are often detected in membrane environments, and
research suggests that helical intermediates are stabilized
by lipids, and that such intermediates encourage stronger
interactions with membranes, enhancing aggrega-
tion.[33,130,131] Experiments have also shown that cholester-
ol-rich lipid environments enhance b-sheet content, likely
the result of lipid-mediated fibril formation.[132] It seems
that the initial species to interact with the membranes is
a-helical and that further aggregation in the membrane
environment allows fibrillation to continue, eventually
leading to b-sheet containing fibrils. It would therefore
appear that a-helical intermediates of CT are key for ag-
gregation in both solution and membrane environments.
Additional work by Diociaiuti and colleagues has im-
plicated lipid rafts as having a crucial role in mediating
the pore formation of sCT oligomers, a behavior observed
in other amyloids, as well.[129] The enrichment in lipid
rafts for cholesterol and GM1 suggests that these mem-
brane components could play a role in mediating interac-
tions, although a role for lipid raft-induced changes in
membrane thickness or curvature has not been ruled
out.[54] Work by Sheynis and Jelinek showed an interest-
ing behavior of CT to form fibril mats on membrane sur-
faces without insertion, in contrast with the amyloid-
b whose lipid-induced fibrillation is associated with a com-
plete membrane rupture.[97,128] While the possible implica-
tions of lipid raft-mediated CT membrane interactions on
pore formation are clear, the potential physiological roles
for fibril mats, if any, remain unknown.
4.3 Prefibrillar Oligomers
Compared with other amyloids, there are relatively few
studies focused on prefibrillar aggregates of CT. Howev-
er, some trends have emerged from the literature. Both
annular and linear protofibrillar aggregates of sCT have
been observed and characterized by Diociauti and col-
leagues, using both TEM and circular dichroism measure-
ments, showing them to be primarily rich in random coil
Table 1. pH-dependent rate constants, k1 and k2, in a two-step autocatalytic reaction mechanism for hCT fibril formation in solution.
Sample Condition k1 (s
@1) k2 (s
@1 M@1) Ref.
Wt-hCT pH 7.5 2.8W10@6 2.3 [98]
Wt-hCT pH 3.3 3.3W10@6 2.4W10@3 [98]
D75N-hCT pH 7.2 1.6W10@5 5.5 [105]
D75N-hCT pH 2.9 6.2W10@7 5.4W10@3 [105]
F16L-hCT pH 7.5 1.9W10@7 4.8W10@2 [106]
F16L-hCT pH 2.6–3.0 1.8W10@6 6.2W10@3 [106]
F19L-hCT pH 7.5 7.4W10@9 2.9W10@2 [106]
F19L-hCT pH 2.6–3.0 1.3W10@6 1.6W10@2 [106]
TL-hCT[a] pH 7.5 3.4W10@6 3.0W10@3 [106]
TL-hCT[a] pH 2.6–3.0 5.4W10@6 4.8W10@3 [106]
Wt-hCT (HEPES) pH 5.6 3.0W10@10 2.0W10@3 [93]
[a] F16L, F19L, Y22L-hCT.
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and b-strand conformation, respectively.[12] Despite the
prevalence of these larger species of prefibrillar aggre-
gates, smaller (<20mer) prefibrillar oligomers are the
species putatively responsible for membrane permeabili-
zation, exhibiting enhanced pore-formation activi-
ty.[12,54,100,109] As with several other amyloid peptides, pore
formation by CT oligomers leads to calcium leakage and
loss of cell homeostasis, with this behavior being modified
by both membrane composition and membrane struc-
ture.[32,33,54,55,89] As mentioned previously, the biological
relevance of such pore formation remains unknown. Of
greater interest therapeutically is the fact that oligomers
are thought to form critical intermediates for further ag-
gregation of CT, making them a potential target for inhib-
ition.[93]
There is a relative lack of structural knowledge on
early oligomers in CT, compared with mature fibrils,
beyond the consistent formation of a central a-helix.
Among the few characterizations of prefibrillar oligo-
mers, an NMR-based structural model for hCT at acidic
pH, obtained by Huang and colleagues, indicates the for-
mation of a b-hairpin structure in the central region, with
an N-terminal loop and unstructured C-terminus.[100] This
structure is believed to be stabilized by aromatic residue
p-p interactions, and is consistent with the structures of
Naito and colleagues, representing a potential intermedi-
ate in the transition from a-helix to b-strand (Figure 5).
However, intermediates containing random coil, a-helix,
and b-hairpin secondary structures have all been detected
in CT oligomers, highlighting the heterogeneity and meta-
stability of early aggregation products and the significant
effect of environmental conditions.[12,100,104] It is likely that
the oligomeric intermediate of Huang and colleagues rep-
resents only one of a number of oligomeric intermediates
formed between monomers and fibers. Amongst these in-
termediates, micelle-like oligomers have been implicated
in the aggregation of several other amyloid peptides, and
unpublished results suggest they may play a role in CT
aggregation, as well.[90,133] Efforts to probe the role of
these possible intermediates are ongoing.
5. Role of Calcitonin Structure and Aggregation
in Biological Function and Therapy
For many of the more widely studied amyloid peptides,
such as amyloid-b and hIAPP, the biological relevance of
their aggregation derives directly from their influence on
disease states. Specifically, the formation of cytotoxic olig-
omers and subsequent cell death is believed to be directly
responsible for several types of dementia and other path-
ologies. While CT has reproducibly demonstrated the
ability to form toxic species in model membrane systems
and cultured cells, to date, the aggregation of CT in or-
ganisms has neither been shown to directly cause signifi-
cant toxicity, nor to drive any disease pathology.[13,30] The
relevance of in vivo CT aggregation is instead primarily
related to its roles in mitigating peptide-receptor interac-
tions and limiting therapeutic efficiency through altera-
tions of peptide structure and bioavailability.
5.1 The Role of CT Structure on Biological Function
Research points to a-helical intermediates as being key
for several essential behaviors of CT. a-helical content is
directly proportional to biological activity in several CT
variants.[14] In the therapeutically relevant sCT, the forma-
tion of an a-helix between residues 9 and 19 may be
a key structural determinant in mediating CT-CTR inter-
actions, with this helix location being consistent with pre-
viously determined structures of sCT.[55,118,119,134] Interest-
ingly, sCT mutants with excess helical content have exhib-
ited decreased receptor binding affinity and hypocalcemic
activity, indicating that the specific length of a-helical do-
mains influences biological function.[121,135] The central a-
helix of hCT is significantly shorter than that of the sCT,
and hCT has shown superior hypocalcemic activity under
aggregation-inhibiting conditions.[36,134] A potential ex-
planation is that the shorter a-helix of hCT is superior for
receptor activation, but either the shorter a-helix or other
structural elements of hCT also render it more prone to
further aggregate. Thus, it appears that there is a balanc-
ing act between monomer potency and stability for CT
and its various isoforms.
Mechanistically, several ideas exist as to how specific
secondary structural elements mediate CT-receptor inter-
actions. The N-terminal tail of CT, the most conserved
section of CT across all species (Figure 1), is believed to
be critical for receptor activation, binding to the CTR
and initiating its cAMP cascade.[50,55,116,121,122] This N-termi-
nal region forms a loop structure in hCT as mentioned,
with this structural motif persisting in a range of solution
conditions. Studies with hCT peptide fragment 9–32 have
shown helix formation upon interactions with membranes,
but have failed to demonstrate spontaneous membrane
insertion without the N-terminal residues, indicating the
potential dual role of such residues in both receptor acti-
vation and membrane insertion.[116] As mentioned previ-
ously, the presence and structure of a-helical motifs is
also correlated with CT biological activity. Additionally,
NMR experiments, along with the well-established ability
of a-helical CT to insert into the membrane, led Rawat
and Kumar to propose that CT could interact with inter-
membrane receptor domains, although such a behavior
would be rare amongst GPCRs.[104] Overall, it is likely
that both the central a-helix and N-terminal loop contrib-
ute to receptor activation.
A role for the C-terminal residues of CT in receptor
binding and activation is less clear, although recent re-
sults suggest they are involved. Johansson and colleagues
recently managed to crystalize sCT C-terminal peptide
fragments bound to the ectodomain of the CTR.[136]
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Using X-ray crystallography, it was found that a type II b-
turn formed involving residues 28–31 of sCT, with this
turn being complementary to a loop consisting of residues
121–128 of the CTR. Hydrogen bonding between sCT
and CTR was also mapped, with stacking between Pro32
of sCT and Trp79 of CTR, in particular, being implicated
as a potential key interaction. Working with similarly
truncated sCT and CTR models, Lee and colleagues like-
wise found C-terminal residues of sCT to form a turn and
hydrogen bond with CTR residues.[50] This work also im-
plicated the stacking of Pro32 of sCT and Trp79 of CTR
as a potentially key mediator of CT-CTR interactions,
with a P32Y mutation in the sCT sequence significantly
weakening binding to the CTR ectodomain. These results
suggest that C-terminal residues of CT could mediate in-
teractions with the CTR.
Despite these recent discoveries, evidence exists that
the C-terminus is not relevant for receptor interactions.
The unstructured nature of the CT C-terminus, along
with the lack of sequence conservation between species,
suggests a minimal role in receptor activation.[55,86,87] C-
terminally mutated hCT peptides have shown no decrease
in receptor binding or hypocalcemic effect, calling into
question whether or not the binding exhibited by Johans-
son and Lee was sufficient for receptor activation.[121,137]
The use of truncated versions of sCT and CTR by Johans-
son and Lee, along with the lack of a membrane environ-
ment and nonevaluation of activation also presents ques-
tions as to the biological relevance of the interactions ob-
served.[50,136] Clearly, further experiments involving CT
and CTRs are necessary to clarify the structure-function
relationship in CT-mediated CTR activation.
5.2 The Role of CT Aggregation in Therapeutic Applications
Owing to its roles in mediating bone reformatting, CT
has been used as a therapeutic in the treatment of the
bone-related diseases osteoporosis and PagetQs disease to
decrease the loss of bone mass and the rate of bone refor-
matting, respectively.[34,138] For details on the history of
CT therapy, the reader is directed to a review by Henrik-
son et al.[139] Typically, sCT has been the most commonly
used isoform in therapeutic applications, owing to its
slower aggregation rate, relative to hCT, which increases
the amount of soluble, bioavailable monomeric peptide.[35]
Despite its slower aggregation relative to hCT, sCT still
aggregates, making it an improvement over hCT, but still
an inefficient therapeutic.[11,106] sCT therapy is also associ-
ated with several side effects, including anorexia and
vomiting, and has been shown to cause antibody forma-
tion and immune response.[37,38,140,141] Such reactions fur-
ther decrease the efficacy of sCT treatments.[142] hCT is
not associated with an immune response, and therefore
modifications to the hCT peptide to increase its bioavail-
ability are an attractive alternative to current sCT thera-
pies.[143]
Promising targets for improving hCT bioavailability are
the central aromatic residues Tyr12, Phe16, and Phe19.
Mutation studies replacing these central aromatic resi-
dues in hCT with Leu (thus increasing homology with
sCT) led to a decrease in the aggregation rate by 2–3
orders of magnitude.[106] The more conservative F19Y mu-
tation had no effect on aggregation kinetics, indicating
that the effect of the central aromatics was general and
not specific to any one amino acid.[106] These findings
were supported by MD simulations.[106] Crucially, such
mutants of hCT maintain their biological function, likely
through stabilization of helical motifs, with both hypocal-
cemic potency and duration being enhanced over wt-hCT
in rat models.[144,145] Given their significant homology to
wt-hCT, it is also unlikely that such mutants would elicit
immune response. Additionally, polyphenols, a popular
class of small molecule inhibitors of amyloid aggregation,
have proven effective in modulating the aggregation of
CT.[100,146] It is believed that such inhibitors operate
through interference with p-p interactions, validating this
region as a potential site for pharmaceutical optimization
and further strengthening arguments for a strong role for
aromatic residues in CT aggregation and remodeling.[100]
Other modifications to hCT could also be made to de-
crease its aggregation propensity. The oxidation state of
methionine at residue 8 in hCT has been shown to alter
its aggregation rate in a pH-independent manner.[147] The
absence of methionine in sCT suggests that a mutation at
residue 8 of hCT could present another avenue for kinet-
ics modification. Investigation by Fowler and colleagues
found that five amino-acid substitutions (T11R, N17R,
N24R, I27T, V29S) in hCT could slow its aggregation to
the rate of sCT, mainly through increasing a-helix stabili-
ty and decreasing peptide hydrophobicity.[121] Additional-
ly, more of this a-helix promoting hCT mutant remained
soluble once aggregation was completed, compared with
wild-type, and the peptide modifications did not adversely
affect receptor binding or the hypocalcemic effect. An-
other study by Andreotti and colleagues found that the
mutation of five central and C-terminally located residues
in hCT to their sCT equivalents (Y12L, N17H, A26N,
I27T, A31T) both decreased the rate of aggregation and
maintained structure and biological function.[137] This
modified hCT also had the ability to inhibit the aggrega-
tion of wild-type hCT when the two were coincubated.[137]
As with the mutations to the aromatic residues of hCT,
the mutants of Fowler and Andreotti would also be ex-
pected to decrease the immune responses endemic of sCT
therapy, given the rarity of antibody formation against
hCT.[143] The decreased immune response and subsequent-
ly decreased secondary resistance would further enhance
the effectiveness of CT therapies. Such mutated hCT var-
iants thus present another potential alternative to sCT
therapies.
CTs interactions with lipid vesicles are also of signifi-
cant interest due to the increasing prevalence of lipid-
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based delivery systems for biomolecular therapeu-
tics.[125,126,147,148] Significant efforts have been made to
modify CTs to enhance their permeability through epithe-
lial layers to increase their effective bioavailability. It ap-
pears that a-helical intermediates would be beneficial to
that end, due to their enhanced membrane insertion abili-
ties. The formation of a-helices by CT is enhanced by
anionic lipids and cholesterol within the bilayer, and
while such CT structures are believed to be key for recep-
tor interactions, a-helical intermediates in the presence of
lipid bilayers also have been shown to drive fibril forma-
tion. A universal answer as to whether or not a-helices
are desirable during drug application thus appears unlike-
ly, and would depend heavily on other factors (other pep-
tide modifications, mode of intake, dosage, etc.). The
choice of lipids in a lipid-based delivery system, particu-
larly the head-group charge, could prove to be an attrac-
tive and simple means of controlling aggregation during
peptide delivery.
Despite the prevalence of helical intermediates, mature
CT fibrils are found to contain primarily a b-sheet secon-
dary structure.[12,32,98–103] The progression of CT monomers
to b-sheet fibrils via a-helical intermediates would seem
to mark such intermediates as a target species for fibrilla-
tion inhibition, but any attempts at modifying CT fibrilla-
tion must be performed with receptor interactions in
mind. As we have discussed, significant evidence exists
showing a-helical intermediates to be key in mediating
peptide-receptor interactions. Therefore, direct inhibition
of helix formation would likely render CT ineffective as
a therapeutic. However, prevention of a further progres-
sion to b-strand morphologies and fiber formation would
leave biological activity intact. The stabilization of helical
intermediates has already been demonstrated in other
systems to prevent fibrillation in vivo and enhance CT
pore formation, indicating an increased bioavailabil-
ity.[89,145,149–151 Furthermore, decreased fibrillation and im-
proved bioavailability and function are observed in a-
helix promoting hCT mutants, and residue-specific data
exists on the effect that modifying helix length and loca-
tion has on peptide function.[121,134,135] Therefore, stabiliz-
ing the formation of a-helical intermediates of CT ap-
pears to be one of the simplest, and least invasive, meth-
ods by which to enhance the bioavailability and efficacy
of CT as a therapeutic.
6. Current Calcitonin Therapy
The availability of more effective osteoporosis drugs, such
as bisphosphonates, has led to CT therapy primarily
being used for the short-term mediation of acute pain
from osteoporosis, although combination treatments in-
volving CT have shown efficacy in mediating both hyper-
calcemia and bone quality under circumstances in which
other treatments were ineffective.[152–155] In particular, CT
has seen significant use as a therapeutic for the treatment
of postmenopausal osteoporosis.[35,152,156,157] Efforts to im-
prove CT efficacy in recent years have primarily focused
on peptide modifications and alternative delivery meth-
ods.
6.1 Peptide Alterations
In addition to preventing aggregation, therapeutic forms
of CT must overcome the obstacle of proteolytic clear-
ance. This clearance is especially rapid in the presence of
gastrointestinal enzymes, with full degradation of both
hCT and sCT occurring within a few hours.[158–161] Experi-
ments by Doschak and colleagues also revealed a 75%
loss of radiolabeled sCT within 3 hours in major tissues in
rat, with near complete loss within 24 hours.[162] Indeed,
the rapid degradation of CT particularly in the digestive
track is a major obstacle to the development of oral for-
mulations. Many prominent alternative oral delivery
methods (detailed below) and peptide modifications are
therefore focused on improving uptake and longevity. PE-
Gylated and N-terminally acylated sCT have both shown
improved resistance and intestinal permeability, with PE-
Gylated sCT also showing increased longevity and a ~3–
5X improvement in hypocalcemic effect in rat
models.[161,163,164] Lipidization has also been used to im-
prove transepithelial transport, with both reversible and
nonreversible additions being explored.[161,162] Reversible
lipidization of sCT maintain more peptide in serum for
longer, with correspondingly longer hypocalcemic activi-
ty.[163] Additionally, nonreversible lipidization has been
shown to alter peptide secondary structure, which would
likely inhibit receptor activation.[161] As such, reversible
lipidizations of sCT appear to be the more promising of
the two for peptide modification.
6.2 Alternative Delivery Methods
Alternatives to injected and nasal spray sCT (the current
preferred methods of administration) are being explored.
The majority of these efforts focus on oral administration
through novel delivery vessels. An oral mucoadhesive
polymer delivery system developed by Gupta and col-
leagues demonstrated significant load delivery in rat in-
testine, and a 50-fold improvement in bioavailability
versus direct intestinal injection.[164] Biodegradable nano-
particles, coated liposomes, and lipid nanocapsules have
all also been shown to produce improved sCT delivery,
both in cultured cells and through oral delivery in
vivo.[125,126,147,148] Despite these advances, phase III clinical
trials of oral delivery methods have failed to demonstrate
statistically significant increases in bone-mineral density
over nasal applications, and thus, the development of oral
delivery methods for sCT remains in progress.[156,157,165]
The efficacy of all sCT treatment methods, including oral
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delivery, is likely still limited by sCTQs aggregation and
limited bioavailability upon absorption.
6.3 CT Therapy and Medullary Thyroid Carcinoma
A commonly mentioned concern regarding the use of CT
in osteoporosis therapy is the correlation of CT fibrils
with medullary thyroid carcinoma (MTC) tumor
cells.[166–168] It has been strongly suggested that CT fibrilla-
tion is a driver of tumor formation and progres-
sion.[30,112,132,146] Several problems exist with this interpreta-
tion, however. MTC is a cancer of the CT-expressing C-
cells, thus one would expect unmitigated cell proliferation
to result in excessive local production of CT and subse-
quent fibril formation. To our knowledge, as of this writ-
ing, there is no evidence in the literature showing CT, fi-
brillar or otherwise, causes MTC, with this idea being fur-
ther challenged by the existence of CT-negative MTC
tumors.[169,170] CTQs use as a biomarker for MTC also sug-
gests it to be an effect, rather than a cause, of MTC, since
elevated CT serum levels occur after tumor forma-
tion.[171,172] Additionally, elevated CT levels do not neces-
sarily correspond to the presence of MTC.[173] The stron-
gest case for an active role in MTC for CT is an analysis
by the Food and Drug Administration and the European
Medicines Agency, finding CT therapy correlates with
cancer risk.[174] However, this correlation was weak (<
1% increase), involved clinical trials much longer than
current typical dosing regimens for short-term use, and
showed no specificity to MTC versus other carcino-
mas.[174] Overall, the fibrillation of CT seems like a conse-
quence, rather than a driver, of MTC.
7. Summary and Outlook
In the 54 years since its discovery, the function of CT in
the body, along with its methods of action, has been well
characterized. Its roles in skeletal protection and hyper-
calcemia prevention have made it an attractive option as
a therapeutic agent, and the last 15 years have seen re-
markable progress in CT research, in both therapeutic
and structural contexts. Peptide modifications and alter-
native delivery methods have increased the bioavailability
and convenience of CT therapy, and through the use of
NMR and other advanced methodologies, the structures
of CT fibers have been illuminated. The effects of lipids
on CT aggregation provides strong potential measures of
control in therapeutic delivery and hints at possible phys-
iological roles for their interactions. Additionally, studies
focusing on the structure and function of early aggrega-
tion intermediates have yielded clues as to their role in
aggregation, and have clarified key secondary structural
motifs for both aggregation and biological activity. Using
this information, CT mutants have been developed which
hold promise as both therapeutics and tools to further un-
derstand CT-receptor interactions.
Despite these facts, significant questions still remain re-
garding CT. While it remains unlikely that CT will sup-
plant more popular long-term osteoporosis treatment op-
tions, such as bisphosphonates, its utility in select circum-
stances merits continued work to improve its immune ef-
fects and limited bioavailability. Efforts to develop oral
CT delivery systems hold particular promise for the
future, with multiple possible candidates undergoing clini-
cal trials. While early events in CT aggregation have re-
ceived more attention recently, as with all amyloid pep-
tides, further studies are required before a functional un-
derstanding of the aggregation intermediates can be con-
structed. In particular, an understanding of the role of the
central a-helix and N-terminal loop of CT in mediating
interactions with the CTR is required. Experiments yield-
ing residue-specific information on the role of the C-ter-
minus in receptor interactions preview an exciting avenue
for further elucidation of the structure-function relation-
ship of CT-CTR interactions. Such information would
greatly aid in informing peptide modifications that de-
crease aggregation while maintaining or enhancing bio-
logical activity. Such CT mutants would prove invaluable
in improving CT therapeutics, regardless of delivery
mechanism. Finally, while this review has considered ag-
gregation in the context of therapeutic applications and
biological function, an understanding of the aggregation
of CT, specifically the lag phase, would provide informa-
tion significant to the broader field of amyloid aggrega-
tion, with relevance to a range of disease pathologies.
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